Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Rituximab in the Treatment of Anti-Vimentin Antibody-associated Diseases

NCT07051070 is registered in ClinicalTrials.gov with Xuanwu Hospital, Beijing as lead sponsor.

NCT NCT07051070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07051070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Rituximab in the Treatment of Anti-Vimentin Antibody-associated Diseases
Lead sponsor
Xuanwu Hospital, Beijing
Phase
Phase 4
Overall status
Not yet recruiting
Start date
July 1, 2025
Completion date
November 1, 2026
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti-vimentin antibody-associated diseases, meningoencephalomyelitis associated with vimentin igg autoantibodies